Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Parkinson Disease: early-phase trial registry
135 of 298 indexed Parkinson Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #31 of 28,707 conditions by registered trial count.
298 US clinical trials · 135 currently recruiting · #31 of 28,707 conditions by registered trial count
Parkinson Disease: 298 US clinical trials tracked, 135 recruiting.
Parkinson Disease is the subject of 298 registered US clinical trials on ClinicalTrials.gov, 135 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 66 in Phase 1-2 (earlier-stage). The most active sponsor is University of Minnesota, running 10 of these trials.
Enrollment posture brief
Registry condition parkinson-disease
OPEN 135 | RECR 45% | LATE 21 | EARLY 66 | RANK #31 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Gastric Cancer (45% recruiting · 159 trials)
Parkinson Disease lists 135 open slots (45% of 298 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Parkinson Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Parkinson Disease is recruiting above its size-band peers.
135 of 298 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Parkinson Disease trials is spread across many organizations.
University of Minnesota accounts for 10 of 298 trials (3.4%). 165 distinct sponsors appear on at least one study for this condition label.
-
Most Parkinson Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 55 among the 298 trials that report a genuine target (sentinel values excluded). 207 of those (69.5%) plan for fewer than 100 participants.
-
Parkinson Disease research is mostly interventional.
226 interventional and 72 observational studies make up this index (75.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
298 total, page 3 of 6
Exercise for Cognitive Excellence in Parkinson's Disease
University of California, San Francisco
NCT05720468
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
Vanderbilt University Medical Center
NCT04620382
Sensory Filtering in the Human Basal Ganglia as a Mechanism of Parkinson's Disease
University of Alabama at Birmingham
NCT05482126
Vibrotactile Coordinated Reset: a Non-invasive Treatment for Parkinson's Disease 2
Synergic Medical Technologies
NCT05881460
Robotic Gait Rehabilitation in Parkinson's Disease
Indiana University
NCT05218187
User-friendliness of a Portable Driving Simulator
University of Kansas Medical Center
NCT03969927
Circuit-Based Deep Brain Stimulation for Parkinson's Disease P1A2&3 Catalyst
University of Minnesota
NCT05658302
Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.
University of Minnesota
NCT06692920
The GBA Multimodal Study in Parkinson's Disease
Pacific Parkinson's Research Centre
NCT04101968
Personalized Real-Time DBS and PD Mechanisms
David Escobar
NCT06013956
Unlocking Movement Potential: Enhancing Parkinson's Disease Treatment With Robotic EksoSkeleton
Albert Einstein Healthcare Network
NCT06225830
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
The Cleveland Clinic
NCT07138560
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
CND Life Sciences
NCT07204652
Imaging Core Aim 2, and Udall Project 2 Aim 2
University of Minnesota
NCT06998303
Effects Of Osteopathic Manipulative Medicine(OMM) On Lower Extremity Muscle Characteristics In Parkinson's Disease(PD) Patients
New York Institute of Technology
NCT05884944
rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease
West Virginia University
NCT06237868
Light Therapy Intervention in Individuals With Parkinson's Disease
University of Delaware
NCT06916260
Spinal Cord Stimulation for Parkinson's Disease Rehabilitation
University of Louisville
NCT06804642
Effects of Transcranial Ultrasound Stimulation (TUS) on Neurological and Cognitive Outcomes in Neurodegenerative Diseases
Sanmai Technologies PBC dba Sanmai
NCT07207122
Real-Time Levodopa Level Monitoring in Parkinson Disease
University of California, San Diego
NCT04735627
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
Allyx Therapeutics
NCT06309147
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
University of Vermont Medical Center
NCT05603715
Endurance Exercise & Virtual Reality for Optimizing Cortical Excitability and Neuroplasticity in PD
The University of Texas Health Science Center at San Antonio
NCT06133283
Neocortical Microarchitecture of Executive Function
University of Colorado, Denver
NCT06778135
SegwayPD: The Effect of Sensory-augmented Postural Training Using Segway on Motor and Cognitive Function in Individuals With Parkinson's Disease
University of Texas Southwestern Medical Center
NCT05982730
Naturalistic Sleep Assessed by Wearable Devices in Parkinson Disease
University of Colorado, Denver
NCT05348837
Correlation of STN-DBS Induced Visuospatial Changes and Freezing of Gait
Medical University of South Carolina
NCT06994728
Effects of RAS on Gait in PD Patients With DBS
Johns Hopkins University
NCT05763732
Deep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in Parkinson's Disease
The Cleveland Clinic
NCT07110376
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
University of Colorado, Denver
NCT06296810
Globus Pallidus Stimulation to Treat Insomnia
Mayo Clinic
NCT04116996
Dual Frequency Stimulation in Parkinson's Disease
University of California, Davis
NCT04650932
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
Jeffrey S. Schweitzer, MD, PhD
NCT06687837
Safety and Feasibility of Tele-supervised Home-based Transcranial Direct Current Stimulation in Parkinson's Disease
Brigham and Women's Hospital
NCT06804668
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
iRegene Therapeutics Co.
NCT07102342
Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)
Sage Bionetworks
NCT02696603
Trial of Parkinson's And Zoledronic Acid
California Pacific Medical Center Research Institute
NCT03924414
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
Biogen
NCT05348785
Community Outreach for Palliative Engagement -- Parkinson Disease
University of Rochester
NCT05222386
DB RCT for Specialized Phototherapy in Parkinson's Disease.
PhotoPharmics
NCT04453033
Automated Imaging Differentiation of Parkinsonism
University of Florida
NCT05913687
A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants with Parkinson's Disease
FAScinate Therapeutics
NCT05670782
Personalizing Exercise for Parkinson Disease
Washington University School of Medicine
NCT04782518
Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status
Global Kinetics Corporation
NCT03741920
Wearable Airbag Technology to Mitigate Falls in Individuals With High Fall Risk
Shirley Ryan AbilityLab
NCT05076565
Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation
Vanderbilt University Medical Center
NCT05933681
Quantitative Imaging of Brain Glymphatic Function in Humans
Vanderbilt University Medical Center
NCT04768101
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)
University of Michigan
NCT05459753
Everyday Memory Impairment in PD-related Cognitive Decline
Washington University School of Medicine
NCT04474379
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
CND Life Sciences
NCT06621602
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 35 |
| Phase 3 | 8 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Parkinson Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Parkinson Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Parkinson Disease page
298 registered trials, 135 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 135 Parkinson Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Minnesota sponsors the most Parkinson Disease trials on record, review their full trial history before evaluating a specific study. See University of Minnesota's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Parkinson Disease condition card totals 298 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.